(S)-(-)-2-(三氟乙酰胺)琥珀酸酐 | 777-33-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-(-)-2-(三氟乙酰胺)琥珀酸酐
• 中文别名: (S)-(-)-2-(三氟乙酰氨基)琥珀酸酐
• 英文名称: N-trifluoroacetyl-L-aspartic acid anhydride
• 英文别名: N-((S)-2,5-dioxo-tetrahydrofuran-3-yl)-2,2,2-trifluoroacetamide；(S)-(-)-2-(Trifluoroacetamido)succinic anhydride；N-[(3S)-2,5-dioxooxolan-3-yl]-2,2,2-trifluoroacetamide
• CAS: 777-33-3
• 化学式: C₆H₄F₃NO₄
• mdl: MFCD00012332
• 分子量: 211.097
• InChiKey: ABTJOHYOWBAGTP-REOHCLBHSA-N

物化性质

• 熔点：
  131-132 °C (lit.)
• 沸点：
  379.2±42.0 °C(Predicted)
• 密度：
  1.60±0.1 g/cm3(Predicted)
• 稳定性/保质期：

  在常温常压下，该物质保持稳定。

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  72.5
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• 安全说明：
  S36,S45
• 危险类别码：
  R25
• WGK Germany：
  3
• 危险品运输编号：
  UN 2811 6.1/PG 3
• 储存条件：
  常温、避光、存放在通风干燥处。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
: (S)-(−)-2-(Trifluoroacetamido)succinic anhydride
Product name
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 777-33-3
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 2), H300
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H300 Fatal if swallowed.
Precautionary statement(s)
P264 Wash hands thoroughly after handling.
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Synonyms : N-Trifluoroacetyl-L-aspartic acid anhydride
(S)-(−)-2-Trifluoroacetamidosuccinic anhydride
Formula : C6H4F3NO4
Molecular Weight : 211,10 g/mol
CAS-No. : 777-33-3
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
(S)-(-)-2-(Trifluoroacetamido)succinic anhydride
CAS-No. 777-33-3 Acute Tox. 2; H300 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
(S)-(-)-2-(Trifluoroacetamido)succinic anhydride
CAS-No. 777-33-3 T, R25 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen fluoride
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 131 - 132 °C - lit.
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents, acids
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. ((S)-(-)-2-(Trifluoroacetamido)succinic anhydride)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. ((S)-(-)-2-(Trifluoroacetamido)succinic anhydride)
IATA: Toxic solid, organic, n.o.s. ((S)-(-)-2-(Trifluoroacetamido)succinic anhydride)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-(-)-2-(三氟乙酰胺)琥珀酸酐 在 氯化亚砜 作用下， 以 乙醚 为溶剂， 反应 0.33h， 生成 ethyl 5-diazo-4-oxo-N-trifluoroacetyl-(2S)-norvalinate
  参考文献：
  名称：

  Field, Steven J.; Young, Douglas W., Journal of the Chemical Society. Perkin transactions I, 1983, # 10, p. 2387 - 2392

  摘要：

  DOI：
• 作为产物：
  描述：

  L-天门冬氨酸 、 三氟乙酸 在 三氟乙酸酐 作用下， 反应 18.5h， 以95%的产率得到(S)-(-)-2-(三氟乙酰胺)琥珀酸酐
  参考文献：
  名称：

  [EN] GRANZYME B DIRECTED IMAGING AND THERAPY
  [FR] IMAGERIE DU GRANZYME B ET THÉRAPIE DIRIGÉES CONTRE LE GRANZYME B

  摘要：

  本文提供了用于成像Granzyme B的杂环化合物。还提供了成像Granzyme B的方法、联合疗法以及包含Granzyme B成像试剂的试剂盒。

  公开号：

  WO2019160916A1

文献信息

• Butyric acid matrix metalloproteinase inhibitors
  申请人：Warner-Lambert Company

  公开号：US06020366A1

  公开（公告）日：2000-02-01

  Compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2 include hydrogen, alkyl, substituted alkyl, halo, and arylalkyl; R.sub.3 is hydroxy, alkoxy, or hydroxyamino; X is O, S, or NOH; and R.sub.4 and R.sub.5 include hydrogen, alkyl, and aryl are useful for inhibiting matrix metalloproteinase enzymes in animals, and as such, prevent and treat diseases resulting from the breakdown of connective tissues.

  式##STR1##中的化合物，其中R.sub.1和R.sub.2包括氢、烷基、取代烷基、卤素和芳基烷基；R.sub.3是羟基、烷氧基或羟基氨基；X是O、S或NOH；R.sub.4和R.sub.5包括氢、烷基和芳基，对于抑制动物体内基质金属蛋白酶酶活性是有用的，因此可以预防和治疗由结缔组织分解引起的疾病。
• Asymmetric and efficient synthesis of homophenylalanine derivatives via Friedel–Crafts reaction with trifluoromethanesulfonic acid
  作者：Ryo Murashige、Yuka Hayashi、Makoto Hashimoto

  DOI：10.1016/j.tetlet.2008.09.013

  日期：2008.11

  reaction of TFA-Asp(Cl)-OMe and stoichiometric amounts of benzene was established by using neat trifluoromethanesulfonic acid (TfOH) as solvent and catalyst under a mild condition. This methodology has been applied to many aromatic compounds and enabled synthesis of several homophenylalanine derivatives.

  通过在温和条件下使用纯三氟甲磺酸（TfOH）作为溶剂和催化剂，可以建立TFA-Asp（Cl）-OMe与化学计量的苯的有效Friedel-Crafts反应。该方法已经应用于许多芳族化合物，并能够合成几种高苯丙氨酸衍生物。
• Regioselective functionalization of chiral nickelacycles derived from N-protected aspartic and glutamic anhydrides
  作者：Ana M. Castaño、Antonio M. Echavarren

  DOI：10.1016/s0040-4039(00)97733-5

  日期：1990.1

  The electrophilic cleavage of the nickelacycles resulting from oxidative addition of Ni(0) complexes to N-protected aspartic and glutamic anhydrides, followed by decarbonylation, gives rise regioselectively to derivatives of α-and β-alanine or α-and γ-aminobutyric acid, respectively.

  通过将Ni（0）络合物氧化添加到N保护的天冬氨酸和谷氨酸酐中，然后脱羰作用，镍环的亲电裂解，使α-和β-丙氨酸或α-和γ-氨基丁酸的衍生物在区域上选择性升高，分别。
• Compounds useful for the preparation of medicaments with phosphodiesterase IV inhibitory activity
  申请人：——

  公开号：US20030195257A1

  公开（公告）日：2003-10-16

  Formula (I) compounds are described, where the groups are defined in the description, as well as processes for their preparation and their use as medicaments, particularly as selective phosphodiesterase IV inhibitors. 1

  描述了Formula (I)化合物，其中群在描述中定义，以及它们的制备过程和用途，特别是作为选择性磷酸二酯酶IV抑制剂的药物。
• An Approach to the Synthesis of anti-β²,³-Amino Acids: Application of β-Trifluoroacetamidoorganozinc Reagents
  作者：Richard Jackson、Hannah Bartrum

  DOI：10.1055/s-0029-1217721

  日期：2009.9

  An approach to the synthesis of ANTI-β 2 , 3 -aminoacids is reported. The key steps involve stereoselective lactonealkylation followed by ring opening with iodotrimethylsilane/ethanolto give iodo esters. Formation of the organozinc reagents from theseiodo esters, followed by either Pd- or Cu-catalysed reaction withelectrophiles gives protected β 2 -aminoacids is reported. The key steps involve stereoselective

  报道了一种合成 ANTI-β2, 3 -氨基酸的方法。关键步骤包括立体选择性内酯烷基化，然后用碘三甲基硅烷/乙醇开环得到碘酯。据报道，由这些碘酯形成有机锌试剂，然后通过 Pd 或 Cu 催化与亲电试剂反应，得到受保护的 β  2 - 氨基酸。关键步骤包括立体选择性内酯烷基化，然后用碘三甲基硅烷/乙醇开环得到碘酯。由这些碘酯形成有机锌试剂，然后通过 Pd 或 Cu 催化与亲电试剂反应，得到受保护的 β  2 , 3 -氨基酸。烯醇化物烷基化中的反式立体化学通过 X 射线晶体学证实了烯丙基化的抗内酯。